Crinetics Pharmaceuticals Stock Probability of Future Stock Price Finishing Under 17.44

CRNX Stock  USD 57.17  0.55  0.97%   
Crinetics Pharmaceuticals' future price is the expected price of Crinetics Pharmaceuticals instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Crinetics Pharmaceuticals performance during a given time horizon utilizing its historical volatility. Check out Crinetics Pharmaceuticals Backtesting, Crinetics Pharmaceuticals Valuation, Crinetics Pharmaceuticals Correlation, Crinetics Pharmaceuticals Hype Analysis, Crinetics Pharmaceuticals Volatility, Crinetics Pharmaceuticals History as well as Crinetics Pharmaceuticals Performance.
For more information on how to buy Crinetics Stock please use our How to Invest in Crinetics Pharmaceuticals guide.
  
At this time, Crinetics Pharmaceuticals' Price To Sales Ratio is fairly stable compared to the past year. Price Book Value Ratio is likely to rise to 4.02 in 2024, whereas Price Earnings Ratio is likely to drop (10.11) in 2024. Please specify Crinetics Pharmaceuticals' target price for which you would like Crinetics Pharmaceuticals odds to be computed.

Crinetics Pharmaceuticals Target Price Odds to finish below 17.44

The tendency of Crinetics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to drop to $ 17.44  or more in 90 days
 57.17 90 days 17.44 
near 1
Based on a normal probability distribution, the odds of Crinetics Pharmaceuticals to drop to $ 17.44  or more in 90 days from now is near 1 (This Crinetics Pharmaceuticals probability density function shows the probability of Crinetics Stock to fall within a particular range of prices over 90 days) . Probability of Crinetics Pharmaceuticals price to stay between $ 17.44  and its current price of $57.17 at the end of the 90-day period is about 71.66 .
Given the investment horizon of 90 days Crinetics Pharmaceuticals has a beta of 0.77 suggesting as returns on the market go up, Crinetics Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Crinetics Pharmaceuticals will be expected to be much smaller as well. Additionally Crinetics Pharmaceuticals has an alpha of 0.0653, implying that it can generate a 0.0653 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Crinetics Pharmaceuticals Price Density   
       Price  

Predictive Modules for Crinetics Pharmaceuticals

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Crinetics Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
54.8557.1759.49
Details
Intrinsic
Valuation
LowRealHigh
53.8956.2158.53
Details
Naive
Forecast
LowNextHigh
56.0358.3460.66
Details
14 Analysts
Consensus
LowTargetHigh
42.6746.8952.05
Details

Crinetics Pharmaceuticals Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Crinetics Pharmaceuticals is not an exception. The market had few large corrections towards the Crinetics Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Crinetics Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Crinetics Pharmaceuticals within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.07
β
Beta against Dow Jones0.77
σ
Overall volatility
3.10
Ir
Information ratio 0.02

Crinetics Pharmaceuticals Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Crinetics Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Crinetics Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
The company reported the previous year's revenue of 4.01 M. Net Loss for the year was (214.53 M) with loss before overhead, payroll, taxes, and interest of (125.49 M).
Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (166.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6.
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Crinetics Pharmaceuticals Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Crinetics Stock often depends not only on the future outlook of the current and potential Crinetics Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Crinetics Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding58.1 M
Cash And Short Term Investments558.6 M

Crinetics Pharmaceuticals Technical Analysis

Crinetics Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Crinetics Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Crinetics Pharmaceuticals. In general, you should focus on analyzing Crinetics Stock price patterns and their correlations with different microeconomic environments and drivers.

Crinetics Pharmaceuticals Predictive Forecast Models

Crinetics Pharmaceuticals' time-series forecasting models is one of many Crinetics Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Crinetics Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Crinetics Pharmaceuticals

Checking the ongoing alerts about Crinetics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Crinetics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
The company reported the previous year's revenue of 4.01 M. Net Loss for the year was (214.53 M) with loss before overhead, payroll, taxes, and interest of (125.49 M).
Crinetics Pharmaceuticals currently holds about 408.51 M in cash with (166.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.6.
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from finance.yahoo.com: Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly

Additional Tools for Crinetics Stock Analysis

When running Crinetics Pharmaceuticals' price analysis, check to measure Crinetics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crinetics Pharmaceuticals is operating at the current time. Most of Crinetics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Crinetics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crinetics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Crinetics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.